Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

6.9300
-0.3300 (-4.55%)
NASDAQ · Last Trade: Jan 10th, 12:18 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close7.260
Open7.445
Bid6.490
Ask7.450
Day's Range6.910 - 7.461
52 Week Range2.890 - 38.25
Volume39,905
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume83,585

Chart

About Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Quantum Biopharma Ltd. is a biotechnology company focused on developing innovative therapies and treatments for a range of diseases, leveraging advanced biopharmaceutical technologies. The company specializes in creating novel drugs and biologics aimed at improving patient outcomes and addressing unmet medical needs in various therapeutic areas. Through a combination of cutting-edge research and strategic partnerships, Quantum Biopharma is actively engaged in bringing its proprietary products from the lab to clinical trials, with the ultimate goal of enhancing healthcare options and improving the quality of life for patients worldwide. Read More

News & Press Releases

Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan Fox
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 9, 2026
Deadline to Lead in Securities Class Action Against Quantum Biopharma Ltd. (QNTM) is February 23, 2026 - Contact Kaplan Fox
NEW YORK, NY - January 9, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 9, 2026
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 8, 2026
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
NEW YORK, NY - January 8, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 8, 2026
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 7, 2026
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026
NEW YORK, NY - January 7, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 7, 2026
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 6, 2026
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026
NEW YORK, NY - January 6, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 6, 2026
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 5, 2026
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit
NEW YORK, NY - January 5, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 5, 2026
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 3, 2026
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit
NEW YORK, NY - January 3, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 3, 2026
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 2, 2026
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit
NEW YORK, NY - January 2, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 2, 2026
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 1, 2026
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit
NEW YORK, NY - January 1, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 1, 2026
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders
NEW YORK, NY - December 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · December 31, 2025
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 31, 2025
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Via Investor Brand Network · December 23, 2025
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial
By Quantum BioPharma · Via GlobeNewswire · December 23, 2025
The market is filled with gapping stocks in Monday's session.chartmill.com
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · December 22, 2025
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
TORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
Via ACCESS Newswire · December 22, 2025
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
By Quantum BioPharma · Via GlobeNewswire · December 22, 2025
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
By Quantum BioPharma · Via GlobeNewswire · December 19, 2025
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlighted in CTV W5 Part 2 Covering Alleged Market Manipulation
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Via Investor Brand Network · December 1, 2025